Howard Smith MD, AMJan 13
RSV Prevention Pays Off Big. Vaccinations and use of antibody therapy has significantly reduced infections and hospitalizations. #rsv #newborns #vaccine #nirsevimab #hospitalization
https://www.instagram.com/p/DTdqupiEeau/
Howard G. Smith MD, AM on Instagram: "RSV Prevention Pays Off Big Maternal RSV vaccination during pregnancy and the use of the RSV antibody nirsevimab for newborns reduces the incidence of RSV infections by more than two-thirds. Researchers at the CDC and leading children’s hospitals studied 5,029 babies during the 2024–2025 RSV season and published their results in the journal JAMA Pediatrics. Among infants younger than six months, maternal RSV vaccination was 70% effective and nirsevimab was 81% effective. RSV hospitalization rates were reduced 41% to 51% among newborns and infants compared with previous rates. The highest reduction of 56% to 63% occurred in newborns and infants aged 0 to 2 months When RSV vaccinations and antibody injections were rolled out nationally, RSV hospitalizations among infants under one year fell by up to half. The largest reduction was seen in newborns and babies under two months, the group at highest risk for severe RSV. Bottom line: mothers….protect your babies with these safe and very effective interventions. https://www.medscape.com/viewarticle/maternal-rsv-vaccine-and-nirsevimab-show-effectiveness-us-2026a10000ah https://jamanetwork.com/journals/jamapediatrics/article-abstract/2843213 #rsv #newborns #vaccine #nirsevimab #hospitalization"

0 likes, 0 comments - drhowardsmithreports on January 13, 2026: "RSV Prevention Pays Off Big Maternal RSV vaccination during pregnancy and the use of the RSV antibody nirsevimab for newborns reduces the incidence of RSV infections by more than two-thirds. Researchers at the CDC and leading children’s hospitals studied 5,029 babies during the 2024–2025 RSV season and published their results in the journal JAMA Pediatrics. Among infants younger than six months, maternal RSV vaccination was 70% effective and nirsevimab was 81% effective. RSV hospitalization rates were reduced 41% to 51% among newborns and infants compared with previous rates. The highest reduction of 56% to 63% occurred in newborns and infants aged 0 to 2 months When RSV vaccinations and antibody injections were rolled out nationally, RSV hospitalizations among infants under one year fell by up to half. The largest reduction was seen in newborns and babies under two months, the group at highest risk for severe RSV. Bottom line: mothers….protect your babies with these safe and very effective interventions. https://www.medscape.com/viewarticle/maternal-rsv-vaccine-and-nirsevimab-show-effectiveness-us-2026a10000ah https://jamanetwork.com/journals/jamapediatrics/article-abstract/2843213 #rsv #newborns #vaccine #nirsevimab #hospitalization".

Instagram
Gute Pillen – Schlechte PillenSep 7, 2025
Das IQWiG führte eine Überprüfung des Nutzens für Kinder ohne erhöhtes Risiko für #RSV-Erkrankungen durch: Die Vorbeugung mit #Nirsevimab verhindert zwar keine Todesfälle, dennoch zeigen sich in der ersten Saison der Kinder deutlich positive Effekte❄️(€)
https://gutepillen-schlechtepillen.de/rsv-impfung-mit-nirsevimab/
RSV-Impfung mit Nirsevimab - Gute Pillen - Schlechte Pillen

Eine RSV-Impfung soll Babys vor schweren Folgen der Infektion schützen. Studien zeigen, dass auch gesunde Säuglinge geimpft werden sollten.

Gute Pillen - Schlechte Pillen
IQWiGJun 2, 2025

#RSVProphylaxe mit #Nirsevimab: Vorteile für gesunde Kinder in der ersten RSV-Saison

Mit dem Antikörper Nirsevimab immunisierte Kinder erkranken deutlich seltener an RSV-bedingten Infektionen der unteren Atemwege.

https://www.iqwig.de/presse/pressemitteilungen/pressemitteilungen-detailseite_148816.html

RSV-Prophylaxe mit Nirsevimab: Vorteile für gesunde Kinder in der ersten RSV-Saison

Mit dem Antikörper Nirsevimab immunisierte Kinder erkranken deutlich seltener an RSV-bedingten Infektionen der unteren Atemwege.

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Global News NationalDec 12, 2024
It’s RSV season in Canada. Here’s how to keep children safe
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
#RSV #health #children #Canada #nirsevimab #respiratorysyncytialvirus
https://globalnews.ca/news/10912730/rsv-antibodies-vaccine-holidays/
It’s RSV season in Canada. Here’s how to keep children safe

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

Global News
Global News CanadaDec 12, 2024
It’s RSV season in Canada. Here’s how to keep children safe
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
#RSV #health #prevention #Canada #nirsevimab #respiratorysyncytialvirus
https://globalnews.ca/news/10912730/rsv-antibodies-vaccine-holidays/
It’s RSV season in Canada. Here’s how to keep children safe

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

Global News
Global NewsDec 12, 2024
It’s RSV season in Canada. Here’s how to keep children safe
As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.
#RSV #health #prevention #Canada #nirsevimab #respiratorysyncytialvirus
https://globalnews.ca/news/10912730/rsv-antibodies-vaccine-holidays/
It’s RSV season in Canada. Here’s how to keep children safe

As the respiratory illness season begins, cases of respiratory syncytial virus (RSV) cases are rising in Canada. But new tools offers hope for prevention.

Global News
Italian News by RSSOct 17, 2024

RaiNews by undefined
Virus sinciziale, da novembre ai neonati l'anticorpo monoclonale. Intesa in stato-regioni

Via libera dalla conferenza Stato-regioni al piano di immunizzazione contro il virus Sinciziale (vrs) per tutti i neonati con l'anticorpo monoclonale Nirsevimab. Sono stati stanziati 50 mln

Translated:
The monoclonal antibody for infants has been available since November to treat respiratory syncytial virus (RSV). An agreement between the government and regions has been reached.

The State-Regions conference has given the green light to the immunization plan against the Syncytial Virus (RSV) for all newborns with the monoclonal antibody Nirsevimab. €50 million have been allocated.

#RSV #Nirsevimab #StateRegions
https://www.rainews.it/articoli/2024/10/da-novembre-ai-neonati-lanticorpo-contro-virus-sinciziale-intesa-in-stato-regioni-ed0c85c0-4620-4f5d-b4c2-1f0cf5a85189.html

Virus sinciziale, da novembre ai neonati l'anticorpo monoclonale. Intesa in stato-regioni

Via libera dalla conferenza Stato-regioni al piano di immunizzazione contro il virus Sinciziale (vrs) per tutti i neonati con l'anticorpo monoclonale Nirsevimab. Sono stati stanziati 50 mln

RaiNews
Italian News by RSSOct 3, 2024

Corriere.it - Homepage by di Ruggiero Corcella
Virus respiratorio sinciziale, campagna in ritardo e solo per  il 75% dei bambini 

Nirsevimab, il nuovo anticorpo monoclonale di Sanofi contro l'infezione nei bambini, sarà disponibile in Italia dal 28 ottobre. Le dosi garantiranno però solo il 75% della copertura di nascite

Translated:
Respiratory syncytial virus, campaign delayed and only for 75% of children.

Nirsevimab, Sanofi's new monoclonal antibody against infection in children, will be available in Italy from October 28th. However, the doses will only guarantee 75% coverage of births.

#Nirsevimab #Sanofi #Italy
https://www.corriere.it/salute/figli-genitori/bambino/24_ottobre_03/virus-respiratorio-sinciziale-la-campagna-di-immunizzazione-con-il-nuovo-farmaco-copriro-parte-in-ritardo-e-coprira-solo-il-75-dei-bambini-interessati-69000122-ddf6-49d3-a0bb-9545db2a9xlk.shtml

Virus respiratorio sinciziale, la campagna di immunizzazione con il nuovo farmaco parte in ritardo e coprirà solo il 75% dei bambini interessati

Nirsevimab, il nuovo anticorpo monoclonale di Sanofi contro l'infezione nei bambini, sarà disponibile in Italia dal 28 ottobre. L'azienda farmaceutica inizierà la distribuzione nei prossimi giorni, ma le dosi garantiranno circa il 75% della copertura dell'intera coorte nazionale di nascite

Corriere della Sera
Diario-Radio UChileJun 28, 2024

Doctor Miguel O’Ryan: “Este año debería quebrarse la tradicional curva crítica de invierno” | #UChileRadio

https://radio.uchile.cl/2024/06/28/doctor-miguel-oryan-este-ano-deberia-quebrarse-la-tradicional-curva-critica-de-invierno/

#migueloryan #movimientoantivacuna #nirsevimab #virusinfluenza #virussincicial

Doctor Miguel O\'Ryan: \"Este año debería quebrarse la tradicional curva crítica de invierno\"

El decano de la Facultad de Medicina de la U. de Chile destacó la incorporación del medicamento Nirsevimab, destinado a combatir el virus sincicial. Asimismo, señaló que \"dentro de todo se logró una cobertura\" de la vacuna contra la influenza.

Diario y Radio Universidad Chile
Show threadInfektionsforschung (HZI)Jun 27, 2024
In einem Press Briefing des Science Media Center Germany ordnet unter anderem Thomas Pietschmann, Virologe am HZI & @TWINCORE, die neue STIKO-Empfehlung zur #RSV-Prophylaxe mit #Nirsevimab ein. https://www.sciencemediacenter.de/alle-angebote/press-briefing/details/news/empfehlung-der-staendigen-impfkommission-zur-rsv-immunisierung/
Empfehlung der Ständigen Impfkommission zur RSV-Immunisierung

Die Stiko empfiehlt, dass alle Säuglinge den monoklonalen Antikörper Beyfortus erhalten sollen. Impfstoffe für Ältere & Schwangere werden nicht empfohlen.